肺肿瘤立体定向体部放疗后心脏功能评估:前瞻性探索性心-肺研究结果
HALO研究为前瞻性单臂多中心观察性试点研究,纳入肿瘤距心脏<3 cm的早期NSCLC或孤立肺转移患者,于SBRT前及后3、12个月用ECG、实验室检查、超声心动图、心脏磁共振和问卷评估心脏功能。8例可分析患者共90个心脏节段,未发现各项检查显著差异;最高心脏剂量节段心肌应变可能恶化,绝对差2.8%。
要点
- 肿瘤距心脏<3 cm的早期NSCLC患者SBRT后12个月内未见临床相关剂量相关心脏不良事件。
- 多模态心脏评估未发现整体心脏功能显著变化,平均心脏剂量4 Gy。
- 最高心脏剂量节段心肌应变可能恶化,绝对差2.8%,但本小型试点研究未观察到剂量依赖效应。
核心结论
- 在平均心脏剂量4 Gy的早期NSCLC患者中,SBRT后12个月多模态心脏评估未观察到临床相关剂量相关心脏不良事件或整体心脏功能显著变化。
- 本小型试点研究未观察到放疗对心肌应变的剂量依赖效应。
研究设计与样本
- HALO研究为前瞻性、单臂、多中心观察性试点研究。
- 纳入计划接受SBRT的1A至2B期NSCLC或孤立肺转移患者,肿瘤距心脏<3 cm。
- 于SBRT前及后3个月、12个月使用ECG、实验室检查、超声心动图、心脏磁共振成像(CMR)和问卷评估心脏功能。
- 采用广义线性模型评估节段放疗剂量与纵向、周向、径向心肌应变随时间变化差值之间的剂量效应。
主要发现
- ECG、实验室检查、超声心动图、CMR或问卷测量均未发现显著差异。
- 剂量效应较小,最高心脏剂量节段心肌应变可能恶化,绝对差为2.8%。
临床怎么用
- 对于肿瘤紧邻心脏的早期NSCLC患者,SBRT后可按计划进行多模态心脏功能随访评估。
- 最高心脏剂量节段的心肌应变变化值得关注,但本试点研究样本量小,尚不足以改变临床决策。
局限性
- 本研究为小型试点研究,仅8例患者纳入分析。
- 平均心脏剂量为4 Gy,结论外推至更高心脏剂量场景受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Several studies show associations between cardiac radiation dose and cardiac morbidity or overall survival. To evaluate cardiac toxicity of radiation therapy in the absence of another cardiotoxic agent, we set up a prospective pilot study evaluating cardiac function using a wide range of diagnostic modalities in early-stage non-small cell lung cancer (NSCLC) patients with a tumor in close proximity to the heart. METHODS AND MATERIALS: The HALO study was a prospective, single-arm, multicenter observational pilot study. Patients scheduled for stereotactic body radiation therapy for stage 1A to 2B NSCLC, or a solitary lung metastasis, with a tumor <3 cm from the heart were included. Cardiac function was evaluated using electrocardiography (ECG), laboratory exams, echocardiography, cardiac magnetic resonance imaging (CMR), and questionnaires at pretreatment and 3 and 12 months poststereotactic body radiation therapy. To assess dose effects, generalized linear models were fitted between segmental radiation dose and strain difference between time points, for longitudinal, circumferential, and radial myocardial strain. RESULTS: Ten patients were included in the study, of whom 8 were included for analysis, yielding 90 cardiac segments for analysis. No significant differences were found in any of the ECG, laboratory exams, echocardiography, CMR, or questionnaire measurements. The dose effects were small and translated to a possible worsening of myocardial strain in the highest cardiac dose segments, with an absolute difference of 2.8%. CONCLUSIONS: In these early-stage NSCLC patients with mean cardiac doses of 4 Gy, no clinically relevant dose-related cardiac adverse events nor significant changes in global cardiac function were observed after multimodal cardiac evaluation during 12 months of follow-up. Dose-dependent effects of radiation therapy on myocardial strain were not observed in this small pilot study.
引用
- Hoeksema WF, Belderbos J, Dieleman EMT, et al. Evaluation of Cardiac Function After Stereotactic Body Radiation Therapy for Lung Tumors: Results of the Prospective Explorative Heart-Lung Study. Adv Radiat Oncol. 2026. PMID: 42824061. doi:10.1016/j.adro.2026.102158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。